Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Tierney

Showing results (41-50 of 43) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 43 results.
JCI Insight|October 8, 2021
Therapeutic MK2 inhibition blocks pathological vascular smooth muscle cell phenotype switchJ William Tierney, Brian C Evans, Joyce Cheung-Flynn, et al.
Health Marketing Quarterly|August 14, 2020
Development of a health communication campaign to promote the Texas prescription monitoring programMichael Mackert, Kathrynn Pounders, Laura E Brown, et al.
Biomaterials|August 31, 2024
Intravascular delivery of an MK2 inhibitory peptide to prevent restenosis after angioplastyJ William Tierney, R Paolo Francisco, Fang Yu, et al.
Pageof 5

Showing results (41-50 of 43) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 43 results.
JCI Insight|October 8, 2021
Therapeutic MK2 inhibition blocks pathological vascular smooth muscle cell phenotype switchJ William Tierney, Brian C Evans, Joyce Cheung-Flynn, et al.
Health Marketing Quarterly|August 14, 2020
Development of a health communication campaign to promote the Texas prescription monitoring programMichael Mackert, Kathrynn Pounders, Laura E Brown, et al.
Biomaterials|August 31, 2024
Intravascular delivery of an MK2 inhibitory peptide to prevent restenosis after angioplastyJ William Tierney, R Paolo Francisco, Fang Yu, et al.
Pageof 5